Valuation: Ondine Biomedical Inc.

Capitalization 71.73M 51.7M 44.36M 41.31M 38.44M 4.67B 77.33M 475M 187M 2.23B 194M 190M 8.18B P/E ratio 2023
-2.01x
P/E ratio 2024 -2.27x
Enterprise value 62.13M 44.78M 38.43M 35.78M 33.29M 4.04B 66.98M 411M 162M 1.93B 168M 164M 7.09B EV / Sales 2023
25.7x
EV / Sales 2024 26.6x
Free-Float
48.54%
Yield 2023 *
-
Yield 2024 -
More valuation ratios * Estimated data
Dynamic Chart
1 day+0.25%
1 week-2.79%
Current month-8.34%
1 month-21.76%
3 months-38.31%
6 months-44.69%
Current year-8.34%
More quotes
1 week 7.61
Extreme 7.61
8.5
1 month 7.61
Extreme 7.61
10.5
Current year 7.61
Extreme 7.61
9
1 year 7.61
Extreme 7.61
18.5
3 years 5
Extreme 5
20.85
5 years 5
Extreme 5
60
10 years 5
Extreme 5
60
More quotes
Manager TitleAgeSince
Chief Executive Officer 64 29/02/2004
President 66 05/01/2009
Chief Operating Officer - -
Director TitleAgeSince
Chairman 64 29/03/2009
Director/Board Member 66 05/01/2009
Chairman 67 06/12/2021
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+0.25%-2.79%-27.09%-55.07% 47.8M
+0.56%-1.61%+10.60%+10.12% 217B
+2.41%-1.03%+15.82%+22.52% 127B
+1.17%+2.80%+45.77%+113.01% 67.88B
+2.93%+2.32%-12.04%-18.93% 59.1B
-1.41%+2.24%+26.03%+95.35% 55.55B
+1.31%+7.37% - - 36.13B
-0.78%-0.57%-11.96%-35.74% 27.18B
+1.69%+1.95%+27.31%+30.80% 25.94B
+1.62%-3.44%+6.07%-34.05% 23.78B
Average +0.39%+0.69%+8.95%+14.22% 63.95B
Weighted average by Cap. +0.31%+0.31%+14.38%+26.38%
See all sector performances

Financials

2023 2024
Net sales 1.2M 867K 744K 693K 645K 78.27M 1.3M 7.96M 3.13M 37.44M 3.25M 3.18M 137M 2.05M 1.48M 1.27M 1.18M 1.1M 133M 2.21M 13.57M 5.34M 63.78M 5.54M 5.42M 234M
Net income -14.41M -10.39M -8.91M -8.3M -7.72M -938M -15.54M -95.42M -37.54M -449M -38.96M -38.15M -1.64B -19.1M -13.76M -11.81M -11M -10.23M -1.24B -20.59M -126M -49.74M -594M -51.62M -50.56M -2.18B
Net Debt -2.44M -1.76M -1.51M -1.41M -1.31M -159M -2.63M -16.15M -6.36M -75.94M -6.6M -6.46M -278M -9.6M -6.92M -5.94M -5.53M -5.14M -625M -10.35M -63.55M -25M -299M -25.95M -25.41M -1.09B
More financial data * Estimated data
Logo Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian life sciences company. The Company is engaged in photodisinfection-based therapies to prevent and treat a range of infections, including those caused by drug-resistant pathogens. Its lead product, Steriwave, is a rapid nasal decolonization therapy that eradicates a broad spectrum of pathogens in the nose in only minutes. Steriwave enables rapid elimination of pathogens associated with healthcare-associated infections (HAIs), reduces the reliance on patient compliance and screening, and eliminates the generation of resistance associated with topical antibiotics and other antimicrobials. It also has several products in development, including treatment of chronic rhinosinusitis, decolonization of burns and wounds, disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia and the development of topical antiviral therapy for the upper respiratory tract, including the reduction of SARS-CoV-2 titre and transmission.
Employees
18
More about the company
Date Price Change Volume
15/01/26 8.020 p +0.25% 6,234
14/01/26 8.000 p 0.00% 0
13/01/26 8.000 p 0.00% 682,325
12/01/26 8.000 p -0.62% 276,000
09/01/26 8.050 p -2.42% 178,146

Delayed Quote London S.E., January 15, 2026 at 09:57 am

More quotes

Annual profits - Rate of surprise